Top

Lung

Published in:

01-06-2014

The Impact of Low Subcutaneous Fat in Patients with Nontuberculous Mycobacterial Lung Disease

Authors: Seok Jeong Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang, Sung Shine Shim

Published in: Lung | Issue 3/2014

Abstract

Background

Nontuberculous mycobacteria (NTM) are pathogens that cause chronic respiratory disease, even in immunocompetent patients. We hypothesized that low subcutaneous fat is a predisposing factor for NTM lung disease.

Methods

Following a retrospective review of medical records from between 2005 and 2012, a total of 148 patients with NTM lung disease and 142 age- and sex-matched controls were enrolled. We evaluated subcutaneous fat using chest computed tomography (CT) scans at the midpole level of the left kidney.

Results

The median age of the patients was 62 years and 60.8 % were female. Approximately 71 % were classified into a nodular bronchiectatic group. The patient group had significantly less subcutaneous fat than the control group (39.3 vs. 53.0 cm², p = 0.001). Patients with both localized disease (43.5 vs. 53.0 cm², p = 0.042) and extensive disease (35.9 vs. 53.0 cm², p < 0.0001) had less subcutaneous fat compared with the control group. No difference in subcutaneous fat was observed with respect to the increasing bacterial load in sputum (p = 0.246). In 20 patients with prominent disease progression during the follow-up period, no significant difference was observed between subcutaneous fat at the initial diagnosis and that at the follow-up CT (36.2 vs. 42.0 cm², p = 0.47).

Conclusion

Our results suggest that lower subcutaneous fat may contribute to host susceptibility to NTM lung disease.

Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacteria diseases. Am J Respir Crit Care Med 175(4):367–416

Marras TK, Chedore P, Ying AM, Jamieson F (2007) Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003. Thorax 62(8):661–666PubMedCentralCrossRefPubMed

Falkinham JO 3rd (2002) Nontuberculous mycobacteria in the environment. Clin Chest Med 23(3):529–551CrossRefPubMed

Aksamit TR (2002) Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med 23(3):643–653CrossRefPubMed

Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, Edwards LJ, Chakraborti S, Knowles MR, Nontuberculous Mycobacteria in Cystic Fibrosis Study Group (2003) Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 167(6):828–834. doi:10.1164/rccm.200207-678OC CrossRefPubMed

Reich JM, Johnson RE (1992) Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 101(6):1605–1609CrossRefPubMed

Dhillon SS, Watanakunakorn C (2000) Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin Infect Dis 30(3):572–575. doi:10.1086/313726 CrossRefPubMed

Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, Israel HL, Figueroa WG, Fish JE (1989) Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 321(13):863–868. doi:10.1056/NEJM198909283211304 CrossRefPubMed

Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, Brown MR, Chernick M, Steagall WK, Glasgow CG, Lin J, Jolley C, Sorbara L, Raffeld M, Hill S, Avila N, Sachdev V, Barnhart LA, Anderson VL, Claypool R, Hilligoss DM, Garofalo M, Fitzgerald A, Anaya-O’Brien S, Darnell D, DeCastro R, Menning HM, Ricklefs SM, Porcella SF, Olivier KN, Moss J, Holland SM (2008) Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 178(10):1066–1074. doi:10.1164/rccm.200805-686OC PubMedCentralCrossRefPubMed

10.

Chan ED, Iseman MD (2010) Slender, older women appear to be more susceptible to nontuberculous mycobacterial lung disease. Gender Med 7(1):5–18. doi:10.1016/j.genm.2010.01.005 CrossRef

11.

Ikegame S, Maki S, Wakamatsu K, Nagata N, Kumazoe H, Fujita M, Nakanishi Y, Kawasaki M, Kajiki A (2011) Nutritional assessment in patients with pulmonary nontuberculous mycobacteriosis. Intern Med 50(21):2541–2546CrossRefPubMed

12.

Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999 (2000). Am J Respir Crit Care Med 161(4):1376–1395. doi:10.1164/ajrccm.161.4.16141

13.

Iseman MD, Buschman DL, Ackerson LM (1991) Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 144(4):914–916CrossRefPubMed

14.

Nevill AM, Winter EM, Ingham S, Watts A, Metsios GS, Stewart AD (2010) Adjusting athletes’ body mass index to better reflect adiposity in epidemiological research. J Sports Sci 28(9):1009–1016CrossRefPubMed

15.

Yuksel I, Sencan M, Dokmetas HS, Dokmetas I, Ataseven H, Yonem O (2003) The relation between serum leptin levels and body fat mass in patients with active lung tuberculosis. Endocr Res 29(3):257–264CrossRefPubMed

16.

Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, Strand MJ, Bai X, Ramamoorthy P, Rothman MS, Nagabhushanam V, McDermott M, Levin AR, Frazer-Abel A, Giclas PC, Korner J, Iseman MD, Shapiro L, Chan ED (2013) Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 187(2):197–205CrossRefPubMed

17.

van den Borst B, Gosker HR, Koster A, Yu B, Kritchevsky SB, Liu Y, Meibohm B, Rice TB, Shlipak M, Yende S, Harris TB, Schols AM (2012) The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. Am J Clin Nutr 96(3):516–526PubMedCentralCrossRefPubMed

18.

van den Borst B, Gosker HR, Schols AM (2013) Central fat and peripheral muscle: partners in crime in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187(1):8–13CrossRefPubMed

19.

Furutate R, Ishii T, Wakabayashi R, Motegi T, Yamada K, Gemma A, Kida K (2011) Excessive visceral fat accumulation in advanced chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 6:423–430PubMedCentralPubMed

20.

Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, Kahn SE (2002) The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51(4):1005–1015CrossRefPubMed

21.

Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE (1982) Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 36(1):172–177PubMed

22.

Saelens BE, Seeley RJ, van Schaick K, Donnelly LF, O’Brien KJ (2007) Visceral abdominal fat is correlated with whole-body fat and physical activity among 8-year-old children at risk of obesity. Am J Clin Nutr 85(1):46–53PubMedCentralPubMed

23.

Ackland TR, Lohman TG, Sundgot-Borgen J, Maughan RJ, Meyer NL, Stewart AD, Muller W (2012) Current status of body composition assessment in sport: review and position statement on behalf of the ad hoc research working group on body composition health and performance, under the auspices of the IOC. Medical Commission. Sports Med 42(3):227–249CrossRefPubMed

24.

Liu X, Ji Y, Chen J, Li S, Luo F (2009) Circulating visfatin in chronic obstructive pulmonary disease. Nutrition 25(4):373–378CrossRefPubMed

25.

Ryu YJ, Lee JH, Chun EM, Chang JH, Shim SS (2011) Clinical outcomes and prognostic factors in patients with tuberculous destroyed lung. Int J Tuberculosis Lung Dis 15(2):246–250

26.

Okumura M, Iwai K, Ogata H, Ueyama M, Kubota M, Aoki M, Kokuto H, Tadokoro E, Uchiyama T, Saotome M, Yoshiyama T, Yoshimori K, Yoshida N, Azuma A, Kudoh S (2008) Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease. Intern Med 47(16):1465–1472CrossRefPubMed

27.

Tasaka S, Hasegawa N, Nishimura T, Yamasawa W, Kamata H, Shinoda H, Kimizuka Y, Fujiwara H, Hirose H, Ishizaka A (2010) Elevated serum adiponectin level in patients with Mycobacterium avium-intracellulare complex pulmonary disease. Respiration 79(5):383–387CrossRefPubMed

28.

Klein S, Coppack SW, Mohamed-Ali V, Landt M (1996) Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 45(7):984–987CrossRefPubMed

29.

Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, Arner P (1998) Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47(6):913–917CrossRefPubMed

30.

Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S et al (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1(11):1155–1161CrossRefPubMed

31.

Lord GM, Matarese G, Howard JK, Bloom SR, Lechler RI (2002) Leptin inhibits the anti-CD₃-driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines. J Leukocyte Biol 72(2):330–338PubMed

32.

De Rosa V, Procaccini C, Cali G, Pirozzi G, Fontana S, Zappacosta S, La Cava A, Matarese G (2007) A key role of leptin in the control of regulatory T cell proliferation. Immunity 26(2):241–255CrossRefPubMed

33.

Wieland CW, Florquin S, Chan ED, Leemans JC, Weijer S, Verbon A, Fantuzzi G, van der Poll T (2005) Pulmonary Mycobacterium tuberculosis infection in leptin-deficient ob/ob mice. Int Immunol 17(11):1399–1408CrossRefPubMed

34.

Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H (2004) Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323(2):630–635CrossRefPubMed

Title: The Impact of Low Subcutaneous Fat in Patients with Nontuberculous Mycobacterial Lung Disease
Authors: Seok Jeong Lee
Yon Ju Ryu
Jin Hwa Lee
Jung Hyun Chang
Sung Shine Shim
Publication date: 01-06-2014
Publisher: Springer US
Published in: Lung / Issue 3/2014
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-014-9565-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Impact of Low Subcutaneous Fat in Patients with Nontuberculous Mycobacterial Lung Disease

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2014

Nontuberculosis Mycobacterium Disease is a Risk Factor for Chronic Obstructive Pulmonary Disease: A Nationwide Cohort Study

Polysomnographic Differences Associated with Pulmonary Hypertension in Patients with Advanced Lung Disease Due to Cystic Fibrosis

Stem Cells Protect the Bronchial Stump in Rat, Increasing Sox6, Col2a1, and Agc1 Expression

Genetic Influence on Capillary Oxygen Saturation: A Twin Study

Interstitial Lung Disease in Patients with Hepatopulmonary Syndrome: A Case Series and New Observations

Economic Evaluation of Exercise Training in Patients with Pulmonary Hypertension

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page